REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis
USA - NASDAQ:REGN - US75886F1075 - Common Stock
681.72 USD
+7.17 (+1.06%)
683.08 USD
+1.36 (+0.2%)
Overall REGN gets a fundamental rating of 7 out of 10. We evaluated REGN against 531 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, REGN could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year REGN was profitable.
REGN had a positive operating cash flow in the past year.
Each year in the past 5 years REGN has been profitable.
REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of REGN (11.40%) is better than 93.97% of its industry peers.
With an excellent Return On Equity value of 14.79%, REGN belongs to the best of the industry, outperforming 94.35% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 8.69%, REGN belongs to the top of the industry, outperforming 93.97% of the companies in the same industry.
REGN had an Average Return On Invested Capital over the past 3 years of 12.44%. This is below the industry average of 15.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
REGN has a Profit Margin of 32.13%. This is amongst the best in the industry. REGN outperforms 96.23% of its industry peers.
In the last couple of years the Profit Margin of REGN has grown nicely.
REGN's Operating Margin of 27.61% is amongst the best of the industry. REGN outperforms 96.23% of its industry peers.
In the last couple of years the Operating Margin of REGN has declined.
With an excellent Gross Margin value of 86.28%, REGN belongs to the best of the industry, outperforming 88.14% of the companies in the same industry.
REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
REGN has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for REGN has been reduced compared to 5 years ago.
Compared to 1 year ago, REGN has an improved debt to assets ratio.
2.2 Solvency
REGN has an Altman-Z score of 6.96. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 6.96, REGN is doing good in the industry, outperforming 77.78% of the companies in the same industry.
The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
REGN has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. REGN outperforms 94.73% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
The Debt to Equity ratio of REGN (0.09) is worse than 63.09% of its industry peers.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 6.96 |
ROIC/WACC1.02
WACC8.51%
2.3 Liquidity
A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.06, REGN is in line with its industry, outperforming 47.46% of the companies in the same industry.
REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN's Quick ratio of 3.51 is in line compared to the rest of the industry. REGN outperforms 43.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
The earnings per share for REGN have decreased by -0.92% in the last year.
The Earnings Per Share has been growing by 13.12% on average over the past years. This is quite good.
Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.55% yearly.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
REGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.65% yearly.
REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.75% yearly.
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.65%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.75%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
REGN is valuated correctly with a Price/Earnings ratio of 15.15.
96.05% of the companies in the same industry are more expensive than REGN, based on the Price/Earnings ratio.
REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.34.
Based on the Price/Forward Earnings ratio of 15.35, the valuation of REGN can be described as correct.
REGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 95.86% of the companies in the same industry.
REGN is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.43, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.15 | ||
| Fwd PE | 15.35 |
4.2 Price Multiples
REGN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. REGN is cheaper than 95.29% of the companies in the same industry.
REGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. REGN is cheaper than 95.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.62 | ||
| EV/EBITDA | 13.42 |
4.3 Compensation for Growth
The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.15
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
5. Dividend
5.1 Amount
With a yearly dividend of 0.54%, REGN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 89.80, REGN pays a better dividend. On top of this REGN pays more dividend than 98.31% of the companies listed in the same industry.
With a Dividend Yield of 0.54, REGN pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
5.2 History
REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
681.72
+7.17 (+1.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner Change-0.2%
Ins Owners1.89%
Ins Owner Change0.18%
Market Cap72.26B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80.59
Price Target747.8 (9.69%)
Short Float %2.87%
Short Ratio2.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)0.38%
PT rev (3m)0.44%
EPS NQ rev (1m)13.43%
EPS NQ rev (3m)13.25%
EPS NY rev (1m)7.41%
EPS NY rev (3m)18.44%
Revenue NQ rev (1m)4.29%
Revenue NQ rev (3m)4.26%
Revenue NY rev (1m)1.73%
Revenue NY rev (3m)5.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.15 | ||
| Fwd PE | 15.35 | ||
| P/S | 5.07 | ||
| P/FCF | 18.62 | ||
| P/OCF | 14.25 | ||
| P/B | 2.33 | ||
| P/tB | 2.44 | ||
| EV/EBITDA | 13.42 |
EPS(TTM)45.01
EY6.6%
EPS(NY)44.42
Fwd EY6.52%
FCF(TTM)36.62
FCFY5.37%
OCF(TTM)47.84
OCFY7.02%
SpS134.43
BVpS292.08
TBVpS279.05
PEG (NY)N/A
PEG (5Y)1.15
Graham Number543.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 6.96 |
F-Score5
WACC8.51%
ROIC/WACC1.02
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.65%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.75%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-14.02%
EBIT Next 3Y4.25%
EBIT Next 5Y8.44%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 7 / 10 to REGN.
What is the valuation status for REGN stock?
ChartMill assigns a valuation rating of 7 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Undervalued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to decline by -6.32% in the next year.